Coherus Biosciences (CHRS) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Salim Syed maintained a Buy rating on Coherus Biosciences (CHRSResearch Report) today and set a price target of $25.00. The company’s shares closed last Tuesday at $10.02.

According to TipRanks.com, Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -18.1% and a 33.9% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Unity Biotechnology.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Coherus Biosciences with a $17.56 average price target.

See the top stocks recommended by analysts >>

Based on Coherus Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $60.12 million and GAAP net loss of $96.08 million. In comparison, last year the company earned revenue of $83.03 million and had a GAAP net loss of $173 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Read More on CHRS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More